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ABSTRACT 
 
Background: ŝĨĨĞƌĞŶƚŝĂů ƉƌŝĐŝŶŐ ? ďĂƐĞĚ ŽŶ ĐŽƵŶƚƌŝĞƐ ? ƉƵƌĐŚĂƐŝŶŐ ƉŽǁĞƌ ? ŝƐ
recommended by the WHO to secure affordable medicines. However, in developing 
countries innovative drugs often have similar or even higher prices than in high-income 
countries. We evaluated the potential implications of trastuzumab global pricing 
policies in terms of cost-effectiveness (CE), coverage and accessibility for patients with 
breast cancer in Latin America (LA). 
 
Methods: A Markov model was designed to estimate life years (LYs), quality-adjusted 
life years (QALYs) and costs from a health care perspective. To better fit local cancer 
prognosis, a base case scenario using transition probabilities from clinical trials was 
complemented with two alternative scenarios with transition probabilities adjusted to 
reflect breast cancer epidemiology in each country. 
 
Findings: Incremental discounted benefits ranged from 0·87 to 1·00 LY and 0·51 to 
0·60 QALY and incremental CE ratios from USD 42,104 to USD 110,283 per QALY (2012 
US dollars), equivalent to 3·6 gross domestic product per capita (GDPPC) per QALY in 
Uruguay and to 35.5 GDPPC in Bolivia. Probabilistic sensitivity analysis showed 0% 
probability that trastuzumab is CE if the willingness-to-pay (WTP) threshold is one 
GDPPC per QALY, and remained so at three GDPPC threshold except for Chile and 
Uruguay (4·3% and 26·6% respectively). Trastuzumab price would need to decrease 
between 69·6% to 94·9% to became CE in LA. 
 
Interpretation: Although CE in other settings, trastuzumab was not CE in LA. The use of 
health technology assessment to prioritize resource allocation and support price 
negotiations is critical to making innovative drugs available and affordable in 
developing countries. 
 
Funding 
Global Health Research Initiative 
Key words: Cost effectiveness, Cost utility, trastuzumab, drug pricing, Latin America. 
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Introduction: 
 
Deaths from non-communicable diseases are projected to rise to 52 million by 2030,
1
 
and it is estimated that 80% of these will occur in low and middle income countries 
(LMIC).)
2
 Access to appropriate technologies is crucial to reverse this trend, but 
unfortunately access to health technology is usually inversely related to health need 
worldwide. Affordability continues to be one of the biggest obstacles for poor people 
and poor countries to gain access to health technology.
3
 
 
Millennium development goal 8E advocates better cooperation with pharmaceutical 
companies to improve access to affordable drugs in LMIC.
4
 Among other measures, 
differential pricing (DP) based on purchasing power parity has been recommended by 
the World Health Organization (WHO) and other institutions as a possible mechanism 
to secure more affordably priced medicines.
5
 DP has been applied to vaccines, as well 
as to HIV drugs and contraceptive products. However, in the case of innovative drugs, 
pharmaceutical companies continue to apply global pricing policies, setting similar 
prices for all countries or even higher prices in lower-income countries.
6, 7
 In Latin 
America (LA) many innovative drugs have higher prices than in high-income countries.
8
 
This is frequently the case with new cancer drugs, meaning that high prices not only 
restrict patients´ access to treatment, but also impose an economic burden on patients 
and their families creating a high risk of catastrophic expenditure and impoverishment. 
Globally, the proportion of the price paid by patients out-of-pocket for 
pharmaceuticals is inversely related to the country´s gross domestic products (GDP).
9
 
 
In this paper, we analyze the case of trastuzumab and the possible impact of global 
pricing policies on patient access. Breast cancer is the most prevalent form of 
malignant disease among women, with an estimated global incidence of 1·05 million 
new cases every year
10
.  In LA, it is estimated that more than 100,000 women will be 
diagnosed with breast cancer every year.
11
 About 10% ?30% of breast cancers over-
express the human epidermal growth factor receptor 2 (HER2/ErbB2), which is 
associated with clinically aggressive disease and a poor prognosis
12
. Trastuzumab 
(Herceptin®) is a humanized monoclonal antibody used in the treatment of breast 
cancer that over-expresses HER2. Its addition to first-line chemotherapy has shown to 
improve time to disease progression and overall survival in randomized, multicentre 
trials.
13
  
 
Several economic evaluations performed in high-income countries have shown that 
trastuzumab is a cost-effective intervention according to local decision-making 
thresholds.
14-24
  Although not without controversy due to its high cost, it has become 
the standard of care for adjuvant therapy in patients with HER2-positive early-stage 
breast cancer in high-income countries. Trastuzumab has been available in LA since 
2000 but its inclusion and financing by ĐŽƵŶƚƌŝĞƐ ? ŚĞĂůƚŚ ĐĂƌĞ ƐǇƐƚĞŵƐ is 
heterogeneous. The concept of value-based pricing to inform price negotiations for the 
particular context and patient group has been applied in some high-income 
countries.
25
 As economic considerations to prioritize resource allocation decisions are 
increasingly being accepted in the LA region,
26, 27
 cost-effectiveness information could 
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be valuable in deciding on the incorporation of trastuzumab to health benefit packages 
or in informing price negotiations. 
 
 
Objectives 
 
The objective of this study was to evaluate the potential implications that current 
pricing policies of trastuzumab might have in terms of cost-effectiveness, coverage and 
accessibility for patients with early HER2-positive breast cancer in seven LA countries: 
Argentina, Bolivia, Brazil, Colombia, Chile, Peru and Uruguay. 
 
 
Methods 
 
The present study was part of a larger project, funded by the Global Health Research 
Initiative.
28
 The project involved the creation of a research network of LA investigators 
and policy-makers in order to select a health technology relevant to participating 
countries´ health policies, perform a multi-country economic evaluation and promote 
the use of the generated evidence in policy making. Trastuzumab was selected, among 
a list of candidate technologies proposed by the participating countries, after 
conducting a prioritization process that involved scoring the candidate technologies 
according to ten predefined attributes (e.g. the disease burden for which the 
technology was proposed, inappropriate variation in practice, equity aspects related to 
access and availability). Once selected, the model structure, required parameters, and 
a common methodology for identifying costs and resource use were developed by 
consensus among the country research teams in two face to face meetings that 
included clinical experts, health economists, epidemiologists and decision makers. A 
literature review of existing health economic evaluations of trastuzumab was 
conducted to inform this process. 
 
A Markov model was programmed in a Microsoft Excel platform using a lifetime 
horizon with yearly cycles. Similar to other published models,
15-17
 the analytical 
ƐƚƌƵĐƚƵƌĞĐŽŶƚĂŝŶƐĨŝǀĞĚŝĨĨĞƌĞŶƚƐƚĂƚĞƐ P ‘ZĞŵŝƐƐŝŽŶ ?Z  ? ‘Loco-ƌĞŐŝŽŶĂůƌĞĐƵƌƌĞŶĐĞ ?(LR) 
including contra-lateral breast cancer ?  ‘ŝƐƚĂŶƚrĞĐƵƌƌĞŶĐĞ ?(DR) including metastasis, 
 ‘ƌĞast cancer dĞĂƚŚ ?ĂŶĚ  ‘Death due to other cĂƵƐĞƐ ?  ?ƐĞĞ&ŝŐ ?  ? ? ?WĂƚŝĞŶƚƐ ŝŶƚŚĞ>Z
state may return to remission after a successful treatment. Breast cancer deaths can 
occur only in patients in the DR state. The effect of trastuzumab was modeled by 
changing the transition probabilities from R and LR to DR, and it was assumed there 
were no cancer recurrences after year 20 of follow up. Although heart failure (HF) is a 
major adverse effect associated with trastuzumab, in order to simplify the analytical 
structure, we did not include a HF state. However, its impact was accounted for by 
adding its weighted influence, according to the incidence of symptomatic HF, to the 
cost and quality of life during the first cycle of active adjuvant trastuzumab therapy. 
Cardio toxicity was assumed to develop during the first cycle, last only one year, be 
reversible in 100% of the patients and produce no additional mortality. 
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A hypothetical cohort of 10,000 women was modeled for each strategy. All the 
individuals enter the model in the R state, are 55 years old, have a HER2-positive early 
breast cancer, which has been completely excised and treated with at least four cycles 
of adjuvant chemotherapy, and are able to receive adjuvant treatment with 
trastuzumab. For model development and reporting we followed the  
recommendations of the International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR)  ? Society for Medical  Decision Making (SMDM) modeling task 
force.
29
  
Cost-effectiveness analysis and derivation of cost-effective price thresholds 
 
The analysis was carried out from the perspective of each country´s healthcare system. 
Cost-utility and cost-effectiveness assessments were carried out to compare the long-
term costs and outcomes of 12 months of adjuvant chemotherapy for HER2-positive 
breast cancer with and without trastuzumab. Cost-effectiveness was evaluated using 
the incremental cost-effectiveness ratio (ICER). ICERs are calculated as the ratio 
between the difference in costs and the difference in benefits between the two 
interventions. Costs include the costs of implementing the strategy (trastuzumab cost, 
HER2 and HF screening), the health care resources used as a result of that strategy (HF 
treatment), minus any medical costs averted (i.e. episodes of cancer recurrence). The 
difference in benefits is the differences in health outcomes between the trastuzumab 
and the non-trastuzumab arm (expressed as LYs or QALYs gained). Thus, the ICER 
reflects the additional cost for each additional unit of outcome obtained as a result of 
using trastuzumab. 
 
In addition to the cost-effectiveness analysis, we also performed a threshold analysis 
to estimate the price that would make trastuzumab cost-effective in each country. For 
the derivation of these cost-effective price thresholds (and, by implication, the value-
based prices), we set a desired incremental cost per QALY gained for each country as 
equal to the per capita GDP. While there is limited scientific evidence on which to 
specify cost-effectiveness thresholds in low and middle income countries, we chose 
this value of one GDP per capita (GDPPC) for several reasons. It has been suggested by 
the WHO as a threshold below which health-care interventions can be considered cost-
effective 
30
 and it is often referenced in Latin America, or used for resource allocation 
decision-making when considering the adoption of new health technologies. For 
example, Mexico explicitly considers one GDP per capita per life year or QALY as the 
maximum acceptable value of the ICER when deciding the inclusion of technologies in 
the public health care system
31
 and is also the threshold to define a technology as cost-
effective in Chile
32
 and Colombia.
33
  
 
This practice is also observed in other parts of the world, where many countries, 
implicitly or explicitly, apply a value close to their national GDP per capita. In the UK, 
the National Institute for Health and Clinical Excellence (NICE) has been using a cost-
effectiveness threshold range between 20,000 and 30,000 pounds per QALY, a figure 
very close to the national GDPPC (26,000 pounds). A similar practice is followed in 
Australia, where the commonly cited threshold is around USD 55,000,
34
 slightly less 
than its GDPPC of USD 66,400. Cost-effectiveness analyses in the USA commonly use a 
figure of USD 50,000-100,000 per life-year or QALY as a threshold for assessing the 
 6 
 
cost-effectiveness of an intervention (GDP per capita in USA is USD 48,300). Although 
it remains a matter of debate, one GDP per capita per life year or QALY is recognized 
almost universally as a threshold below which an intervention can certainly be 
regarded as cost-effective. In the sensitivity analysis, we also evaluated the results 
under a three GDPPC threshold, since this is the upper bound of the threshold range 
suggested by the WHO. 
Expected future costs and benefits were converted to present values through 
discounting. Following the recommendations of most LA guidelines
35
 , costs and effects 
were discounted at a rate of 5% per annum. 
 
Epidemiological, Effectiveness, Safety and Quality of life data 
 
For the base case analysis, the transition probabilities between states, clinical benefit 
of trastuzumab and risk of cardiac toxicity were estimated from the results of the HERA 
trial.
36-38
 The model was calibrated until the overall survival and disease-free survival 
curves at five years were within +/-2·5% of the values of the trial. A hazard ratio of  
0·59 for trastuzumab was used for the first 5 years. Since no evidence was available for 
a longer time horizon, we decided not to model additional benefits of trastuzumab 
beyond this period. 
 
After a search of primary preference-based studies, the quality of life weights were 
obtained from two studies that used the EQ-5D index,
39
 one in breast cancer patients
16
 
and another in patients with symptomatic heart failure.
40
 Age-specific death rates for 
all other causes were obtained from each country´s National Vital Statistics. General 
model input parameters are shown in table 1 and country specific parameters in table 
2. 
 
Resource use and Costs 
Cost estimations were based on a micro-costing approach. The process was guided by 
a common costing template which had previously been designed and validated 
amongst the country teams. Public sector sources such as registries and hospital 
charges were used in all countries. When necessary, inflation adjustments were 
applied using local Consumer Price Indexes (CPI). The total cost of the treatment with 
trastuzumab was calculated considering a first dose of 8mg/kg, followed by 16 doses of 
6mg/kg for an average woman weighing 63 kg and including a drug wastage rate of 
10%. In the first year, the R state in the trastuzumab arm also included the cost of 
routine HF screening for all patients, the weighted cost of HF treatment, and the 
weighted cost of the HER2+ tests needed to identify the patients in each cohort, 
according to the local HER2+ prevalence in each country. All costs were expressed in 
2012 US dollars (USD). See table 2. 
Alternative scenario analyses 
In addition to the base case analysis, two different scenarios were developed to 
account for the structural uncertainty of extrapolating trial data to each country´s 
specific epidemiological situation. 
 
Alternative scenario 1: in this scenario transition probabilities (from R to LR, from R to 
DR and from LR to DR) were calibrated to obtain, in the non-trastuzumab arm, five-
 7 
 
year survival rates similar to those expected in each country for a cohort of patients 
with the same characteristics of those included in trastuzumab clinical trials. The 
estimation of these expected survival rates was based on Globocan data
41
, the relative 
risk of death of each breast cancer stage and HER2+ patients from international 
studies,
42, 43
 the proportion of HER2+ cases
44-48
 and the mix of breast cancer stages at 
diagnosis in each country. In this scenario the absolute clinical benefit of trastuzumab 
turns out to be greater, as it has the same relative effect (HR=0·59) but on higher 
patient risks, since disease prognosis is poorer in LA countries as compared to clinical 
trial data. Therefore, this scenario is favorable to trastuzumab. 
 
Alternative scenario 2: this scenario uses, for the non-trastuzumab arm, the same 
transition probabilities estimated for the alternative scenario 1, but the transition 
probabilities for the trastuzumab arm are adjusted in order to obtain an absolute 
benefit of trastuzumab for each country similar to the absolute benefit observed in 
clinical trials: 
 
TpTz2 = TpNT1  ? (TpNTb  ? (TpNTb x HR) 
 
TpTz2: transition probability for the trastuzumab arm in scenario 2 
TpNT1: Transition probability for the non-trastuzumab arm from scenario 1 
TpNTb: Transition probability for the non-trastuzumab arm in the base case 
HR: Base Case Hazard ratio of trastuzumab 
(TpNTb  ? (TpNTb x HR) is the absolute benefit (i.e. absolute reduction in the transition 
probabilities) attributable to trastuzumab in the base case (i.e. using clinical trials 
data). This value subtracted to the transition probabilities of scenario 1 result in the 
new transition probabilities for scenario 2. 
 
This scenario is more conservative in terms of the benefits of trastuzumab since 
adjustment results in a smaller effect of trastuzumab, in relative terms, than that 
observed in the clinical trials. Adjusted transition probabilities for scenarios 1 and 2 are 
shown in table 2. 
 
Sensitivity Analysis: 
A deterministic sensitivity analyses (DSA) was performed to estimate the impact of 
uncertainty on results by varying each parameter separately into a specific range of 
values. The most influential parameters in the DSA were included in a probabilistic 
sensitivity analysis where all inputs were varied simultaneously across 10,000 Monte 
Carlo simulations, according to specific probability distributions.  Ranges and 
distributions are detailed in table 1.  
 
Results 
 
dŚĞ ĂĚĚŝƚŝŽŶ ŽĨ  ? ? ŵŽŶƚŚƐ ? ĂĚũƵǀĂŶƚ ƚƌĞĂƚŵĞŶƚ ǁŝƚŚtrastuzumab was both more 
effective and more costly than standard care in all countries and all scenarios. In the 
base case analysis, undiscounted results showed that trastuzumab results in a gain 
ranging from 1·67 to 2·13 LYs or 1·05 to 1·36 QALYs, at an incremental cost of USD 
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23,374 to USD 60,741 per patient in a lifetime horizon across countries. Corresponding 
discounted values were 0·87 to 1·00 LY; 0·51 to 0·60 QALYs; and USD 24,700 to USD 
60,800, representing a cost per QALY gained that ranges from USD 42,100 to USD 
110,300 (Table 3). These incremental cost-effectiveness ratios (ICERs), expressed in 
terms of gross domestic products per capita (GDPPC) per QALY gained, ranged from 
3·6 in Uruguay to 35·5 in Bolivia.  
 
In the alternative scenarios, the main differences were in the estimation of benefits. 
These variations affected the ICERs between +/-25% as compared to the base case 
scenario. The first alternative scenario showed results more favorable to trastuzumab, 
with a discounted incremental benefit and cost that ranged from 1·05 to 1·26 life 
years; 0·67 to 0·87 QALYs; and USD 26,087 to USD 61,102, which corresponded to an 
ICER between USD 30,600 to USD 87,200 or 2·6 to 27·2 GDPPC per QALY in Uruguay 
and Bolivia respectively. In the second alternative scenario, the most conservative in 
terms of trastuzumab effect, discounted incremental benefit and cost ranged from 
0·65 to 0·88 life years; 0·38 to 0·53 QALYs; and USD 25,701 to USD 61,277, which 
corresponded to an ICER between USD 63,800 to USD 142,800 or 5·5 to 43·8 GDPPC 
per QALY. (Please, refer to Supplementary Table 1 for further details on results per 
scenario).  
 
The deterministic sensitivity analysis (DSA) showed consistent results across countries. 
Supplementary Figure 1 summarizes the results of the DSA in a tornado diagram. The 
most influential parameters were the discount rate, the HR of trastuzumab and the 
cost of trastuzumab treatment. These parameters, along with other 18 variables, were 
included in the probabilistic sensitivity analysis (PSA). The PSA showed a 0% probability 
of trastuzumab being cost effective if the willingness-to-pay (WTP) threshold is one 
GDPPC per QALY. This result was consistent across all countries and in the three 
different scenarios analyzed. Under a WTP threshold of three GDPPC per QALY, the 
probability of trastuzumab being cost effective continued to be zero in all countries 
except for Chile and Uruguay, where the values were 4·3% and 26·6% respectively. The 
cost-effectiveness acceptability curves per country can be seen in Supplementary 
Figure 2). 
 
We also estimated an indicative in-country price for one 440 mg vial of trastuzumab at 
which trastuzumab would be cost-effective for a willingness to pay per QALY of one 
GDPPC. Table3 shows this, and compares these results to the current selling prices of 
trastuzumab in each country. In order to be cost-effective, under this one GDPPC per 
QALY threshold, the selling price of trastuzumab would need to decrease between 
69·6% in Uruguay to 94·9% in Bolivia. 
 
 
Discussion 
 
The results of our analyses show that in these seven LA countries the ICER of 
trastuzumab ranged from USD 42,000 to USD 110,000 per QALY gained. In terms of 
current dollars, these results are slightly higher than those obtained in economic 
evaluations (EEs) of trastuzumab in high-income countries,
14-24
 although the 
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differences are not large. This is explained by the similar differences in cost and in 
benefits reported in these previous EEs. According to our model, the use of 
trastuzumab may produce an incremental benefit of 0·51 to 0·60 QALYs. These values 
are similar to the ones obtained in EEs carried out in UK, Finland or Canada (0·5, 0·7 
and 0·6 QALYs, respectively),
21, 23, 24 
even though we used a slightly higher discount 
rate. In our study, trastuzumab cost, one of the most important components to explain 
the cost difference in trastuzumab EE, was between 25·6 and 61·3 thousand dollars. 
These values were also comparable to those reported in other EEs (33·5, 44·3, and 51·7 
thousand dollars in UK, Finland or Canada respectively).
21, 23, 24
 
 
However, although the difference in cost, the difference in benefits, and the resulting 
ICERs look quite similar in terms of current dollars to those observed in high-income 
countries, their interpretation differs dramatically when analyzed in the context of 
these LA countries. This becomes apparent when the cost-effectiveness is expressed in 
terms of GDP per capita as the decision threshold. Several EE of trastuzumab 
performed in high-income countries found ICERs close to one GDPPC per QALY (1·5, 
0·8, 1·1, and 1·5 GDPPC per QALY in Finland, USA, UK, and Canada respectively).
21, 23, 24, 
49
 Therefore, they generally concluded that trastuzumab was a cost-effective 
intervention. However, even though we obtained ICERs for LA that were broadly 
similar in terms of current dollars, they were very far from this threshold of one GDPPC 
per QALY, ranging from 3·6 GDPPC per QALY in Uruguay to 35·5 GDPPC per QALY in 
Bolivia. 
 
There is a relationship between the wealth of countries and their level of health care 
expenditure. In fact, less wealthy countries typically spend smaller proportions of their 
GDP in health care. Therefore, there is no reason to expect that, when judging the 
cost-effectiveness of interventions, poorer countries would apply higher thresholds (in 
terms of GDPPC per QALY) than those used in high-income countries. This becomes 
evident if we measure the cost-effectiveness in terms of per capita health 
expenditures, where the gap between our results and those obtained in high-income 
countries becomes even greater. In the EEs of trastuzumab performed in USA, UK, 
Finland and Canada the ICERs obtained were between 5·4 and 16·1 times the mean 
value that ĐŽƵŶƚƌŝĞƐ ?ŚĞĂůƚŚĞǆƉĞŶĚŝƚƵƌĞƉĞƌĐĂƉŝƚĂƉĞƌǇĞĂƌ. In contrast, according to 
our study, LA countries would need to spend an equivalent to  ? ? ? ? ?hƌƵŐƵĂǇ ?to  ? ? ? ? ?
(Bolivia) yearly health expenditures per capita to gain one additional QALY using 
trastuzumab. Supplementary Figure 3 shows the ICERs of trastuzumab in terms of 
yearly health expenditures per head in each country. 
 
Currently, almost all countries in LA tend to provide universal coverage. Within the 
limit of their economic possibilities, they are also willing to cover access to innovative 
therapies. The use of economic evidence to prioritize resource allocation is becoming 
increasingly accepted in LA
26, 27
 and the role of cost-effectiveness information is 
becoming more important to support price negotiations and to decide whether or not 
to incorporate health technologies into health benefit packages. Just as Mexico has set 
a threshold of one GDPPC per life year or QALY to determine whether a product is 
cost-effective or not and to decide on its incorporation into the healthcare system,
31
 it 
is expected that the rest of the countries in the region will also begin to consider a 
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threshold between one and three GDPPC, as recommended by the WHO
30
 and similar 
to those explicitly or implicitly used in high-income countries. Under this scenario, if 
global pricing policies continue to set similar prices internationally, it will be very 
unlikely for innovative drugs to be cost-effective in LA or other developing countries. 
 
In LMIC innovative drugs can be expected to have similar clinical effectiveness to that 
observed in high-income countries, although it may also be substantially lower due to 
less developed health systems, compliance issues or other factors. But, in most cases, 
they will have much more unfavorable cost difference ratios. While in high-income 
countries the costs avoided by fewer recurrences or complications can offset much of 
the additional cost imposed by the new pharmaceuticals, this is not usually the case in 
LMIC, whose medical costs are proportionally much lower. This inevitably entails 
similar or higher ICERs in current dollars, and much higher ICERs and less cost-effective 
results in terms of GDPPC.  
 
Therefore, LMIC may not provide access to these new pharmaceuticals if they begin to 
evaluate cost-effectiveness to inform coverage decisions, unless they adopt 
significantly higher cost-effectiveness thresholds, such as 5 or 10 or more GDPPC per 
QALY, which does not sound reasonable nor sustainable. So, LMIC will need to 
negotiate lower prices, more related to their ĐŽƵŶƚƌŝĞƐ ? ŝŶĐŽŵĞ, to make new health 
technologies available for their population. Drug price is the only component of the 
equation of cost-effectiveness that can be modified to achieve ICERs more consistent 
with local decision-making thresholds in LMIC. This concept of value-based pricing of 
drugs, or approval based on incremental cost-effectiveness in relation to average 
national income, is being used in some high-income countries, and constitutes a 
promising method for setting limits on the cost of new cancer treatments worldwide.
25
 
Its application in LMIC is an even more urgent need. 
 
Our study has several limitations. We took several steps to ensure our model results 
appropriately reflect the actual situation in each country. Despite these efforts, the 
lack of good quality local information about breast cancer epidemiology, health 
resource utilization, unit costs and utilities of different health states are a major 
limitation of our study and increase the uncertainty of our estimates. However, in spite 
of these limitations, and as shown in the sensitivity analysis, the results seem robust. 
At its current price in LA, adjuvant trastuzumab for early breast cancer in HER2-positive 
women is a health intervention that cannot be considered cost-effective under current 
standards, despite having proven to be highly cost-effective in high-income countries. 
In July 2012  the Brazilian government decided to fund the use of trastuzumab within 
its public health system.
50
 However, since the price of trastuzumab in Brazil was 62% 
higher than the international average, and 115% higher than the price prevailing in the 
United States, the decision was made conditional on achieving a price reduction of 
63%. 
 
The problem presented here does not only concern Latin America. While trastuzumab 
is the standard of care in most high-income countries and generally found to be cost-
effective, it remains controversial in many due to its high costs, as do many other new 
drugs. Also, the problem is not confined to trastuzumab. Many other new and 
 11 
 
expensive cancer treatments are currently being funded with public resources in LA, 
many of which have shown in high-income countries much more unfavorable cost-
effectiveness profiles than trastuzumab. LA countries that are currently providing 
coverage to trastuzumab and other innovative drugs might be paying a very high 
opportunity cost in terms of benefits forgone, due to the fact that they are allocating 
their resources to non-cost-effective interventions. Danzon et.al 
51
 suggest that one 
way out of this impasse would be to apply differential pricing, based on local 
assessments of value for money, as described in this paper. The implication is that rich 
countries would pay higher prices than poorer ones, either through an explicit process 
agreed by all, or on the understanding that individual country prices would remain 
confidential. 
 
There is a clear awareness that cancer will become a major disease burden in LA 
countries.
52
 To improve the affordability of key drugs and health technologies, while 
maintaining incentives for innovation, will be one of the main challenges to reduce the 
burden of non-communicable diseases in the coming decades, in rich and poor 
countries alike. Various strategies have been proposed to secure affordable priced 
medicines
53
 and increase access to cancer care
54
 and their discussion is beyond the 
scope of this paper. But beyond the many choices available to governments and health 
systems, health technology assessment should play a central role.  The rigorous 
evaluation of the cost-effectiveness of interventions to prioritize resource allocation 
and support price negotiations is critical to make innovative drugs available and 
affordable in developing countries. 
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